133 related articles for article (PubMed ID: 35577568)
21. Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment.
Campagnolo M; Ferrari S; Dalla Torre C; Cabrini I; Cacciavillani M; Lucchetta M; Ruggero S; Toffanin E; Cavallaro T; Briani C
J Neuroimmunol; 2015 Apr; 281():1-4. PubMed ID: 25867460
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
23. Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Scott LJ
Target Oncol; 2019 Oct; 14(5):493-504. PubMed ID: 31542870
[TBL] [Abstract][Full Text] [Related]
24. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
Léger JM; Viala K; Nicolas G; Créange A; Vallat JM; Pouget J; Clavelou P; Vial C; Steck A; Musset L; Marin B;
Neurology; 2013 Jun; 80(24):2217-25. PubMed ID: 23667063
[TBL] [Abstract][Full Text] [Related]
25. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.
Renaud S; Gregor M; Fuhr P; Lorenz D; Deuschl G; Gratwohl A; Steck AJ
Muscle Nerve; 2003 May; 27(5):611-5. PubMed ID: 12707982
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Castillo JJ; Allan JN; Siddiqi T; Advani RH; Meid K; Leventoff C; White TP; Flynn CA; Sarosiek S; Branagan AR; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Patterson CJ; Hunter ZR; Davids MS; Furman RR; Treon SP
J Clin Oncol; 2022 Jan; 40(1):63-71. PubMed ID: 34793256
[TBL] [Abstract][Full Text] [Related]
27. Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years.
Benedetti L; Garnero M; Demichelis C; Grandis M; Briani C; Beltramini S; Bellucci M; Prada V; Massa F; Gastaldi M; Schenone A; Franciotta D
J Neuroimmunol; 2019 Dec; 337():577081. PubMed ID: 31677562
[TBL] [Abstract][Full Text] [Related]
28. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater AP; Wu JQ; Kipps T; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Dubois J; Eldering E; Mellink C; Van Der Kevie-Kersemaekers AM; Kim SY; Chyla B; Punnoose E; Bolen CR; Assaf ZJ; Jiang Y; Wang J; Lefebure M; Boyer M; Humphrey K; Seymour JF
J Clin Oncol; 2020 Dec; 38(34):4042-4054. PubMed ID: 32986498
[TBL] [Abstract][Full Text] [Related]
30. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
Moreno-Martínez E; De la Serna-Torroba J; Escudero-Vilaplana V; Hernández-Rivas JÁ; Sánchez-Cuervo M; Sánchez-Hernández R
Farm Hosp; 2022 Apr; 46(3):121-132. PubMed ID: 36183205
[TBL] [Abstract][Full Text] [Related]
31. Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Deng R; Gibiansky L; Lu T; Li X; Lu D; Li C; Girish S; Wang J; Boyer M; Shankar N; Humphrey K; Freise KJ; Salem AH; Seymour JF; Kater AP; Miles D
Leuk Lymphoma; 2020 Jan; 61(1):56-65. PubMed ID: 31549889
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies.
Magy L; Kaboré R; Mathis S; Lebeau P; Ghorab K; Caudie C; Vallat JM
J Immunol Res; 2015; 2015():450391. PubMed ID: 26065001
[TBL] [Abstract][Full Text] [Related]
33. High prevalence of the
Vos JM; Notermans NC; D'Sa S; Lunn MP; van der Pol WL; Kraan W; Reilly MM; Chalker J; Gupta R; Kersten MJ; Pals ST; Minnema MC
J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):1007-1009. PubMed ID: 29018161
[No Abstract] [Full Text] [Related]
34. IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom's macroglobulinaemia and medullary carcinoma of the thyroid.
Yang Y; Canepa C
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33622752
[TBL] [Abstract][Full Text] [Related]
35. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies.
Vallat JM; Magy L; Ciron J; Corcia P; Le Masson G; Mathis S
Expert Rev Neurother; 2016 Sep; 16(9):1111-9. PubMed ID: 27267749
[TBL] [Abstract][Full Text] [Related]
37. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Cramer P; Fürstenau M; Robrecht S; Giza A; Zhang C; Fink AM; Fischer K; Langerbeins P; Al-Sawaf O; Tausch E; Schneider C; Schetelig J; Dreger P; Böttcher S; Kreuzer KA; Schilhabel A; Ritgen M; Brüggemann M; Kneba M; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Haematol; 2022 Oct; 9(10):e745-e755. PubMed ID: 35988545
[TBL] [Abstract][Full Text] [Related]
38. B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy.
Benedetti L; Zardini E; Briani C; Beronio A; Gastaldi S; Jarius S; Mancardi GL; Schenone A; Franciotta D
J Neurol Neurosurg Psychiatry; 2011 Nov; 82(11):1291-4. PubMed ID: 21172861
[TBL] [Abstract][Full Text] [Related]
39. Immunochemotherapy versus rituximab in anti-myelin-associated glycoprotein neuropathy: A report of 64 patients.
Nivet T; Baptiste A; Belin L; Ghillani-Dalbin P; Algrin C; Choquet S; Lamy T; Morel V; Musset L; Roos-Weil D; Viala K; Leblond V; Baron M
Br J Haematol; 2022 Jul; 198(2):298-306. PubMed ID: 35420717
[TBL] [Abstract][Full Text] [Related]
40. [Anti-myelin-associated glycoprotein antibody positive IgM monoclonal gammopathy related peripheral neuropathy: 11 cases and literature review].
Gao XM; Jia MN; Qian M; Ren HT; Zhang L; Shen KN; Cao XX; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):901-905. PubMed ID: 31856437
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
